Trial · NCT07899970
Eye Dominance-based Visual Training
NCT07899970, Not applicable, Not yet recruiting, Istinye University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Eye Dominance-based Visual Training. Trials, record NCT07899970. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07899970
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Eye Dominance-based Visual Training
- NCT number
- NCT07899970
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Istinye University
- Conditions
- Eye Dominance-based Visual Training, Volleyball Players
- Interventions
- Eye Dominance-Based Visual Training, Standard Volleyball Warm-up
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Seated Medicine Ball Throw Distance | Baseline (pre-intervention) and immediately after the single intervention session | Upper body explosive power is assessed with the seated overhead medicine ball throw test. The participant sits with the back against a wall and the legs extended, then throws a 2-kg medicine ball. The distance from the wall to the landing point is measured in centimeters. The test is done three times and the best throw is recorded. |
| Primary | Nelson Hand Reaction Time | Baseline (pre-intervention) and immediately after the single intervention session | Visual-motor reaction time is assessed with the Nelson Hand Reaction Test. The participant sits with the dominant elbow resting on a table and catches a vertically dropped ruler released without warning. The catch distance (cm) is recorded over five trials. The highest and lowest values are discarded and the remaining three are averaged. Reaction time is calculated as t = √(2d/g). |
| Primary | Closed Kinetic Chain Upper Extremity Stability Test (CKCUEST) Score | Baseline (pre-intervention) and immediately after the single intervention session | Upper extremity stability and shoulder girdle neuromuscular control are assessed with the Closed Kinetic Chain Upper Extremity Stability Test. In a push-up position (modified for females) with the hands 90 cm apart, the participant alternately touches the opposite hand for 15 seconds. The test is done three times with 45-second rest intervals, and the mean number of touches is recorded. |
| Primary | Scapular Muscle Endurance Test (SMET) Holding Time | Baseline (pre-intervention) and immediately after the single intervention session | The endurance of the middle and lower trapezius and rhomboid muscles is assessed with the Scapular Muscle Endurance Test. Facing a wall, with the elbows flexed to 90° and a bar placed between the elbows, the participant applies 1 kg of external rotation force to a dynamometer and holds the position as long as possible. The test ends if the bar falls, 90° elbow flexion is lost, or discomfort occurs. The best holding time (seconds) from two trials is recorded. |
| Primary | Eye Dominance Determined by the Miles Test | Baseline (before the intervention) | Eye dominance is determined with the Miles test. With arms extended, the participant forms a triangle with the thumbs and index fingers and, with both eyes open, focuses on a target about 3 meters away. The eyes are then closed one at a time; the eye that keeps the target aligned within the triangle is recorded as dominant (right/left). The test is done under controlled indoor lighting. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07899970
GET https://conductscience.org/api/trials/v1/NCT07899970/registered